-transparent.png){kind=logo}
One hundred and thirty-two patients with rheumatoid arthritis treated with gold have been studied for possible associations between HLA DR antigens and different adverse reactions occurring during such therapy. Patients possessing HLA DR3 had a significantly greater frequency of side effects than patients lacking this antigen. It was particularly noticed that DR3 positive patients on gold treatment had an 11 times higher risk of getting proteinuria than those without DR3. The lowest frequency of side effects was seen in DR7 positives. No significant differences between the DR antigen groups with respect to skin eruptions, liver reactions, or leucopenia were evident.
Related Publications
J T Gran, and
G Husby, and
E Thorsby
February 1984,
The Journal of rheumatology,
J T Gran, and
G Husby, and
E Thorsby
December 1986,
Arthritis and rheumatism,
J T Gran, and
G Husby, and
E Thorsby
June 1984,
Arthritis and rheumatism,
J T Gran, and
G Husby, and
E Thorsby
October 1984,
The Journal of rheumatology,
J T Gran, and
G Husby, and
E Thorsby
June 1986,
Disease markers,
J T Gran, and
G Husby, and
E Thorsby
January 1986,
Rheumatology international,
J T Gran, and
G Husby, and
E Thorsby
December 1993,
Casopis lekaru ceskych,
J T Gran, and
G Husby, and
E Thorsby
April 1988,
Casopis lekaru ceskych,
J T Gran, and
G Husby, and
E Thorsby
January 1986,
Scandinavian journal of rheumatology,
J T Gran, and
G Husby, and
E Thorsby
February 1986,
Tissue antigens,
